Syndax Pharmaceuticals
SNDX
Insider trades and stock quote 2024-2026
All insider trades at Syndax Pharmaceuticals
| Date |
Type |
Insider |
Position |
Ø-Price |
Volume |
|
7/8/2026
|
Sell |
Metzger, Michael A. |
Chief Executive Officer |
$24.2 |
$784,776 |
|
6/12/2026
|
Sell |
Botwood, Nicholas A.j. |
Head of R&D, CMO |
$18.1 |
$566,603 |
|
6/11/2026
|
Sell |
Botwood, Nicholas A.j. |
Head of R&D, CMO |
$18.0 |
$617,040 |
|
6/1/2026
|
Sell |
Metzger, Michael A. |
Chief Executive Officer |
$19.0 |
$130,025 |
|
6/1/2026
|
Sell |
Goldan, Keith A. |
Chief Financial Officer |
$19.0 |
$22,351 |
|
2/9/2026
|
Sell |
Goldan, Keith A. |
Chief Financial Officer |
$21.0 |
$71,705 |
|
2/9/2026
|
Sell |
Metzger, Michael A. |
Chief Executive Officer |
$21.0 |
$360,819 |
|
2/6/2026
|
Sell |
Goldan, Keith A. |
Chief Financial Officer |
$20.6 |
$42,931 |
|
2/6/2026
|
Sell |
Metzger, Michael A. |
Chief Executive Officer |
$20.6 |
$152,835 |
|
9/8/2025
|
Sell |
Metzger, Michael A. |
Chief Executive Officer |
$16.4 |
$2,582,021 |
|
8/18/2025
|
Sell |
Podlesak, Dennis |
Director |
$15.8 |
$304,170 |
|
8/15/2025
|
Sell |
Podlesak, Dennis |
Director |
$15.5 |
$298,408 |
|
8/14/2025
|
Sell |
Podlesak, Dennis |
Director |
$14.2 |
$272,521 |
|
7/16/2025
|
Sell |
Metzger, Michael A. |
Chief Executive Officer |
$9.3 |
$69,953 |
|
7/16/2025
|
Sell |
Goldan, Keith A. |
Chief Financial Officer |
$9.3 |
$12,033 |
|
5/19/2025
|
Buy |
Katkin, Keith |
Director |
$9.1 |
$91,120 |
|
5/19/2025
|
Buy |
Huber, Martin H. Jr. |
Director |
$9.0 |
$44,950 |
|
5/19/2025
|
Buy |
Goldan, Keith A. |
Chief Financial Officer |
$0.0 |
$0 |
|
5/16/2025
|
Buy |
Botwood, Nicholas A.j. |
Head of R&D, CMO |
$9.0 |
$105,826 |
|
3/4/2025
|
Sell |
Metzger, Michael A. |
Chief Executive Officer |
$15.0 |
$117,564 |
|
2/10/2025
|
Sell |
Gallagher, Neil |
President, Head of R&D |
$15.5 |
$71,597 |
|
2/10/2025
|
Sell |
Metzger, Michael A. |
Chief Executive Officer |
$15.5 |
$206,017 |
|
2/10/2025
|
Sell |
Goldan, Keith A. |
Chief Financial Officer |
$15.5 |
$58,559 |
All information without guarantee! No recommendation/consultation! © U.S. Securities and Exchange Commission (SEC)
Free Updates via Email
Please confirm your email address